Stock Analysis

Curis Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

Source: Shutterstock

Curis (NASDAQ:CRIS) Full Year 2022 Results

Key Financial Results

  • Revenue: US$10.2m (down 4.6% from FY 2021).
  • Net loss: US$56.7m (loss widened by 25% from FY 2021).
  • US$0.61 loss per share (further deteriorated from US$0.50 loss in FY 2021).
NasdaqGM:CRIS Earnings and Revenue Growth March 15th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Curis EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 1.6%.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 16% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 5 warning signs for Curis (1 is concerning!) that you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether Curis is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis